The firm, a spin-out of Barts Cancer Institute, is developing a mass spec-based test for identifying AML patients likely to respond to the drug midostaurin.
A proteogenomic analysis by a Moffitt Cancer Center-led team uncovered three subtypes of squamous cell lung cancer and treatment approaches to investigate.
The DoD and VA-led initiative is moving beyond its initial focus on lung cancer to add analyses of multiple cancer types and a prospective, multisite study.
The firm also aims to commercialize a new version of its PraediCare Dx platform, which will directly detect heterodimer protein complexes on a tumor cell's surface.
Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.
Illumina’s BaseSpace Sequence Hub (BSSH) supports primary and secondary analysis of massively parallel sequencing data and can be applied to gene panel data that is generated as part of a clinical cancer assay performed in a pathology lab.
